H.C. Wainwright analyst Yi Chen raised the firm’s price target on Alpha Tau (DRTS) to $12 from $9 and keeps a Buy rating on the shares after Japan’s Ministry of Health, Labour and Welfare granted ...
Following an incredibly productive 2025, culminating in several significant announcements in recent weeks, I wish to share with you an updated comprehensive picture of Alpha Tau’s position and ...
Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Alpha Tau Medical Ltd (DRTS – Research Report). The associated price target remains the same with $9.00. Yi Chen has given his ...
Alpha Tau Medical Ltd. (“Alpha Tau”) is a medical technology start-up focused on the research, development, and commercialization of its Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) ...
Hosted on MSN
Alpha Tau expands Alpha DaRT into recurrent prostate cancer: What investors should watch
Alpha Tau Medical Ltd (DRTS) announced an update on their ongoing clinical study. Study Overview – Alpha Tau Medical Ltd. (NASDAQ: DRTS) is launching a new safety study titled “A Safety Study of ...
- FDA approval of IDE to conduct a U.S. pilot study exploring the use of Alpha DaRT in patients with recurrent glioblastoma multiforme (GBM), a highly aggressive brain cancer - - Multiple U.S.
- Receipt of critical license marks significant milestone for first commercial-scale manufacturing facility for Alpha DaRT ®, the innovative alpha-radiation cancer therapy designed for potent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results